KKR-owned Healthium, Temasek-backed Romsons Eye Majority Stake in BL Lifesciences

The transaction is expected to be valued at INR 1,800-2,000 Cr, although the final valuation and deal structure could change as discussions progress.

KKR-owned Healthium Medtech and Temasek-backed Romsons Group have emerged as the key contenders for a 70-80% stake in Delhi-based medical devices company BL Lifesciences, with the transaction likely to value the fourth-generation family-owned business at INR 1,800-2,000 Cr.

The proposed deal has put BL Lifesciences at the centre of interest from two established medical technology players as they look to expand their presence across India’s medical devices market. KPMG is advising the BL Lifesciences promoters on the stake sale.

BL Lifesciences has built its business around medical devices and consumables used across cardiac surgery, critical care, interventional cardiology, anaesthesia and surgical care.

Its portfolio includes perfusion systems such as heart-lung packs, oxygenators and cardioplegia sets, along with cath-lab kits, central venous catheters and invasive pressure-monitoring systems.

The company also distributes a wider range of surgical products, including blood bags, surgical instruments and wound-care products, giving it exposure across several hospital departments and procedural settings.

Its established distribution network and presence in specialised medical-device segments are understood to be among the factors attracting strategic interest.

For Healthium Medtech, the potential acquisition would add to a portfolio that spans wound care, surgical sutures, orthopaedics and other medical technologies. KKR acquired Healthium in 2024 for INR 7,000 Cr after outbidding a consortium comprising Mankind Pharma, ChrysCapital and Novo Holdings.

Romsons Group, meanwhile, has a longstanding presence in medical consumables and devices in India. The company is backed by Temasek, the Singapore-based investment firm, and has been expanding its healthcare manufacturing and product portfolio.

The transaction is expected to be valued at INR 1,800-2,000 Cr, although the final valuation and deal structure could change as discussions progress.

Stay tuned for more such updates on Digital Health News